Sacituzumab Tirumotecan Meets Overall Survival Endpoint

Merck reported November 20 that global Phase 3 TroFuse-015 met its primary overall-survival endpoint in third-line or later advanced gastroesophageal adenocarcinoma. The trial did not meet blinded-review progression-free survival, making the topline positive for…




